

## **Opto Circuits' subsidiary, Eurocor, successfully showcases Drug Eluting Balloon to Asian cardiologists**

**Singapore| Bengaluru July 7 , 2010**

Eurocor GmbH, the 100 per cent German subsidiary of Opto Circuits , hosted two live cases and a successful symposium on the concept of a drug-eluting balloon (DEB) – DIOR® PTCA catheter, at the 6th Asian Interventional Cardiovascular Therapeutics (AICT) 2010 in Singapore. Leading physicians from Asia and Europe gathered in Marina Bay Sands (the exhibition venue) to share their experience on DIOR® and to discuss its wide ranging indications for in-stent restenosis (ISR), acute myocardial infarctions (AMI), small vessel stenting and bifurcation lesions.

The first live case for in-stent restenosis was performed by Dr. Adrian F Low from National University Heart Centre, Singapore; the patient had 3 lesions and was treated using 3 drug-eluting balloons. The second live case for a bifurcation lesion was performed by Dr. Dato Rosli from Malaysia and Dr. Praveen Chandra from India. DIOR® was used in both the live cases and these were very successful.

The Symposium - "**DIOR® - Drug Eluting Balloon (DEB) - Concept to Clinical application**" was hosted by Eurocor GmbH at the Congress. Dr. Peter Stella from Netherlands presented the data from the *Drug Eluting Balloon In Bifurcation Trial* (DEBUIIT) on the application of DIOR® in the treatment of bifurcation lesions. DEBUIIT is a multi-centre clinical study which compared the effectiveness of DIOR® when used in combination with a bare metal stent (BMS) vs. other treatment options involving drug-eluting stents and uncoated balloon catheters. The study results showed very strong and significant clinical advantages provided by DIOR® in bifurcated lesions and it demonstrated significantly reduced rates of binary restenosis and related complications.

Speaking on the Asian market, Mr. Sreerangan Kurup, Managing Director, Eurocor GmbH said, "The cardiovascular device segment in South-East Asia has been growing at a rate of 10-15%. AICT has provided us with an excellent platform to showcase our European experience and technical know-how in the market. "

The use of DIOR® has also drastically reduced the duration of anti-platelet therapy to 3 months when compared to a drug-eluting stent which requires anti-platelet therapy of 12 months or more, thereby reducing post-procedure medication costs for the patients too.

### **About DIOR®**

DIOR® is a drug (paclitaxel)-eluting breakthrough balloon dilatation catheter developed by scientists at Eurocor and used by hundreds of interventional cardiologists across the world. It can be effectively used in patients with in-stent restenosis, bifurcation lesions and lesions in small vessels.

DIOR® is manufactured out of Europe and is sold in Europe, Middle East and South Asia. Eurocor was the first to receive a CE approval for a DEB and the first to launch such a device into world markets.

More information available at: [http://www.eurocor.de/products/dior/product information/](http://www.eurocor.de/products/dior/product%20information/)

### **About AICT**

AICT 2010 was organized by the National University Heart Centre. The Congress showcased the latest advances in coronary interventional technology in the form of live demonstrations, lectures and interactive sessions with experts.

More information available at: <http://www.aict2010.org/>